1. Home
  2. ALGS vs BRNS Comparison

ALGS vs BRNS Comparison

Compare ALGS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALGS
  • BRNS
  • Stock Information
  • Founded
  • ALGS 2018
  • BRNS 2016
  • Country
  • ALGS United States
  • BRNS United Kingdom
  • Employees
  • ALGS N/A
  • BRNS N/A
  • Industry
  • ALGS Biotechnology: Pharmaceutical Preparations
  • BRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALGS Health Care
  • BRNS Health Care
  • Exchange
  • ALGS Nasdaq
  • BRNS Nasdaq
  • Market Cap
  • ALGS 64.8M
  • BRNS 55.9M
  • IPO Year
  • ALGS 2020
  • BRNS 2021
  • Fundamental
  • Price
  • ALGS $7.21
  • BRNS $1.16
  • Analyst Decision
  • ALGS Strong Buy
  • BRNS Strong Buy
  • Analyst Count
  • ALGS 2
  • BRNS 1
  • Target Price
  • ALGS $60.00
  • BRNS $3.00
  • AVG Volume (30 Days)
  • ALGS 99.6K
  • BRNS 50.8K
  • Earning Date
  • ALGS 11-06-2025
  • BRNS 11-06-2025
  • Dividend Yield
  • ALGS N/A
  • BRNS N/A
  • EPS Growth
  • ALGS N/A
  • BRNS N/A
  • EPS
  • ALGS N/A
  • BRNS N/A
  • Revenue
  • ALGS $3,174,000.00
  • BRNS $14,969,000.00
  • Revenue This Year
  • ALGS N/A
  • BRNS N/A
  • Revenue Next Year
  • ALGS N/A
  • BRNS N/A
  • P/E Ratio
  • ALGS N/A
  • BRNS N/A
  • Revenue Growth
  • ALGS N/A
  • BRNS 1766.46
  • 52 Week Low
  • ALGS $3.76
  • BRNS $0.64
  • 52 Week High
  • ALGS $46.80
  • BRNS $2.92
  • Technical
  • Relative Strength Index (RSI)
  • ALGS 28.33
  • BRNS 39.52
  • Support Level
  • ALGS $9.25
  • BRNS $1.20
  • Resistance Level
  • ALGS $8.76
  • BRNS $1.38
  • Average True Range (ATR)
  • ALGS 0.77
  • BRNS 0.12
  • MACD
  • ALGS -0.30
  • BRNS -0.02
  • Stochastic Oscillator
  • ALGS 2.68
  • BRNS 15.00

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.

Share on Social Networks: